Proteome Sciences plc (PRM) Ordinary 1p

Sell:4.02pBuy:5.00p0.02p (0.45%)

Prices delayed by at least 15 minutes
Sell:4.02p
Buy:5.00p
Change:0.02p (0.45%)
Prices delayed by at least 15 minutes
Sell:4.02p
Buy:5.00p
Change:0.02p (0.45%)
Prices delayed by at least 15 minutes

Company Information

About this company

Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.

Key people

Christopher D. J. Pearce
Executive Chairman of the Board, Chief Executive Officer
Stefan Fuhrmann
Finance Director
Ian H. Pike
Chief Scientific Officer, Executive Director
Richard Dennis
Executive Director, Chief Commercial Officer
Martin Diggle
Non-Executive Director
Roger Steven Mcdowell
Independent Non-Executive Director
Ursula M. Ney
Independent Non-Executive Director
Click to see more

Key facts

  • EPIC
    PRM
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB0003104196
  • Market cap
    £14.76m
  • Employees
    35
  • Shares in issue
    295.18m
  • Exchange
    London Stock Exchange (LON)
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.